消瘀康胶囊联合依达拉奉治疗急性脑梗死的临床研究  

Clinical study on Xiaoyukang Capsules combined with edaravone in treatment of acute cerebral infarction

作　　者：王超 丁俊杰[2] 周明锴[3] 涂小峰 WANG Chao;DING Jun-jie;ZHOU Ming-kai;TU Xiao-feng(Zhengzhou Emergency Medical Rescue Center,Zhengzhou 450016,China;Department of Emergency,People’s Hospital of Zhengzhou,Zhengzhou 450003,China;Intensive Care Unit,The Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China;Department of Emergency,the 7th People’s Hospital of Zhengzhou,Zhengzhou 450003,China)

机构地区：[1]郑州市紧急医疗救援中心,河南郑州450016 [2]郑州人民医院急诊科,河南郑州450003 [3]郑州大学第二附属医院重症医学科,河南郑州450014 [4]郑州市第七人民医院急诊科,河南郑州450003

出　　处：《现代药物与临床》2022年第3期508-512,共5页Drugs & Clinic

基　　金：河南省医学科技攻关计划项目(LHGJ20200737)。

摘　　要：目的 观察消瘀康胶囊联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法 选择2019年7月—2021年3月郑州人民医院接收的90例急性脑梗死患者,根据信封抽签法将患者分为对照组和治疗组,每组各45例。对照组静脉滴注依达拉奉注射液,30 mg溶于0.9%氯化钠溶液100 mL中,0.5 h内滴注结束,1次/d。治疗组在对照组治疗基础上口服消瘀康胶囊,3~4粒/次,3次/d。两组患者均连续治疗14d。观察两组临床疗效,对比两组治疗前后的美国国立卫生研究院脑卒中量表(NIHSS)评分以及血清炎症因子和氧化应激指标。结果 治疗后,治疗组的总有效率(95.56%)比对照组的总有效率(75.56%)高(P<0.05)。治疗后,两组NIHSS评分较治疗前下降(P<0.05),且治疗组NIHSS评分低于对照组(P<0.05)。治疗后,两组血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)水平较治疗前下降(P<0.05),治疗后治疗组的TNF-α、IL-1β水平低于对照组(P<0.05)。治疗后,两组血清过氧化物歧化酶(SOD)水平升高,丙二醛(MDA)水平下降(P<0.05);治疗后治疗组SOD水平高于对照组,MDA水平低于对照组(P<0.05)。结论 消瘀康胶囊联合依达拉奉注射液治疗急性脑梗死具有较好的疗效,可减轻神经功能损伤,控制炎症反应,减轻机体氧化应激。Objective To observe the therapeutic effect of Xiaoyukang Capsules combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients(90 cases) with acute cerebral infarction in People’s Hospital of Zhengzhou from July 2019 to March 2021 were divided into control and treatment groups according to the envelope lottery method, and each group had 45 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into 0.9% sodium chloride solution,end of infusion within half an hour, once daily. Patients in the treatment group were po administered with Xiaoyukang Capsules on the basis of the control group, 3 — 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS scores and serum inflammatory factors and oxidative stress indexes in two groups were compared. Results After treatment, the total efficacies of the treatment group(95.56%) was higher than that of the control group(75.56%)(P < 0.05). After treatment, the NIHSS score of two groups were lower than that before treatment(P < 0.05), and the NIHSS score of the treatment group was lower than that of the control group(P < 0.05). After treatment, the serum levels of TNF-α and IL-1βin the two groups were decreased(P < 0.05), and the levels of TNF-α and IL-1β in the treatment group were lower than those in the control group(P < 0.05). After treatment, the serum level of SOD in two groups were increased, but the serum level of MDA in two groups were decreased(P < 0.05). After treatment, the serum level of SOD in the treatment group was higher than that in the control group, but the serum level of MDA in the treatment group was lower than that in the control group(P < 0.05). Conclusion Xiaoyukang Capsules combined with Edaravone Injection has clinical curative effect in treatment of acute cerebral infarction, can reduce nerve function injury, control inflammatory reaction,and reduce oxidative stress.

关 键 词：消瘀康胶囊 依达拉奉注射液 急性脑梗死 NIHSS评分 炎症因子 肿瘤坏死因子-α 白细胞介素-1β 氧化应激指标 丙二醛 过氧化物歧化酶 

分 类 号：R971[医药卫生—药品]